title: [Preventive chemotherapy after transurethral prostatectomy: a randomized study].
abstract: The usefulness of preventive chemotherapy was studied in transurethrally prostatectomized patients with no prior urinary tract infections. They were divided into two groups (A and B) randomized by the envelope method. A was administered intravenously piperacillin (PIPC) 2 g once after surgery, and twice on the following day. B was similarly administered PIPC intravenously, followed by oral administration of tosufloxacin tosilate (TFLX) 300 mg twice daily from the second to the fifth day. Of the total of 135 cases, 104, 45 in A and 59 in B, conformed to the patient standards established for analysis. Efficacy was assessed by the primary physician and also according to a unified standard in which the onset of a post-surgical infection and a bacteriuria of 10(4) or greater CFU/ml observed ten days after surgery were regarded as ineffective. An intergroup statistically significant difference was not observed in the efficacy rate assessed by the primary physician. However, according to the unified standard assessment, B showed a significantly higher efficacy rate (88.1%) than A (62.2%). The administration of TFLX following PIPC was useful. With an indwelling catheter, B exhibited a significantly greater efficacy rate when the retention period was four days or longer. The efficacy was greater in both groups if lavage was not performed, and this effect was greater in A. Consequently, the administration of TFLX was considered more useful for long-term indwelling catheter cases. Neither serious side effects, nor clinical test abnormalities were observed in this study.
authors.affiliation: Department of Urology, Faculty of Medicine, Kyoto University.
authors.forename: O
authors.initials: O
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Arai
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
authors.forename: T
authors.initials: T
authors.lastname: Fukuyama
authors.forename: S
authors.initials: S
authors.lastname: Hida
authors.forename: T
authors.initials: T
authors.lastname: Ikeda
authors.forename: T
authors.initials: T
authors.lastname: Okabe
authors.forename: S Y
authors.initials: SY
authors.lastname: Kuo
authors.forename: T
authors.initials: T
authors.lastname: Kounami
authors.forename: T
authors.initials: T
authors.lastname: Nakagawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D009287:Naphthyridines / Q000627:therapeutic use*; D010878:Piperacillin / Q000627:therapeutic use*; D011292:Premedication / Q000379:methods; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000601:surgery*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C055185:tosufloxacin; D010878:Piperacillin